Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors

被引:5
作者
Wong, Ka Kit [1 ]
Frey, Kirk A. [1 ]
Niedbala, Jeremy [1 ]
Kaza, Ravi K. [1 ]
Worden, Francis P. [2 ]
Fitzpatrick, Kellen J. [1 ]
Dewaraja, Yuni K. [1 ]
机构
[1] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Endocrine Oncol, Ann Arbor, MI 48109 USA
关键词
Ga-68-DOTATATE; Lu-177-DOTATATE; neuroendocrine tumor; PET/CT; peptide receptor radionuclide therapy; SPECT/CT; SUV; theranostics; RECEPTOR RADIONUCLIDE THERAPY; SST1-SST5; DOSIMETRY; SUBTYPES; PRRT;
D O I
10.1097/MNM.0000000000001592
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Our goal is to quantitatively compare radiotracer biodistributions within tumors and major normal organs on pretherapy Ga-68-DOTATATE PET to post-therapy Lu-177-DOTATATE single-photon emission computed tomography (SPECT) in patients receiving peptide receptor radionuclide therapy (PRRT). Methods PET/CT at similar to 60 min postinjection of Ga-68 DOTATATE and research Lu-177-SPECT/CT imaging similar to at 4h (SPECT1) and similar to 24h (SPECT2) post-cycle#1 were available. Manual contours of lesions on baseline CT or MRI were applied to co-registered SPECT/CT and PET/CT followed by deep learning-based CT auto-segmentation of organs. Tumor-to-normal organ ratios (TNR) were calculated from standardized uptake values (SUV)(mean) and SUVpeak for tumor, and SUVmean for non-tumoral liver (nliver), spleen and kidney. Results There were 90 lesons in 24 patients with progressive metastatic neuroendocrine tumor. The correlation between PET and SPECT SUV TNRs were poor/moderate: PET versus SPECT1 R-2 =0.19. 0.21, 0.29; PET versus SPECT2 R-2 =0.06, 0.16, 0.33 for TNRnliver,TNRspleen, TNRkidney, respectively. Across all patients, the average value of the TNR measured on PET was significantly lower than on SPECT at both time points (P<0.001). Using SUVmean for tumor, average TNR values and 95% confidence intervals (CI) were PET: TNRnliver =3.5 [CI: 3.0-3.9], TNRspleen =1.3 [CI. 1.2-1.5], TNRkidney = 1.7 [CI: 1.6-1.9]; SPECT1: TNRnliver = 1.0 [CI: 8.2-11.7], TNRspleen = 2.9 [CI: 2.5-3.4]. TNRkidney = 2.8 [CI: 2.3-3.3]; SPECT2: TNRnliver = 1 6.9 [CI: 1 4-1 9.9], TNRspleen =3.6 [CI: 3-4.2], TNRkidney = 3.6 [CI: 3.0-4.2]. Comparison of PET and SPECT results in a sphere phantom study demonstrated that these differences are not attributed to imaging modality. Conclusions Differences in TNR exist for the theranostic pair, with significantly higher SUV TNR on Lu-177 SPECT compared with Ga-68 PET. We postulate this phenomenon is due to temporal differences in DOTATATE uptake and internalization in tumor as compared to normal organs. (C) 2022 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:892 / 900
页数:9
相关论文
共 50 条
  • [21] Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors
    Oziel-Taieb, S.
    Ferrara, R.
    Charrier, N.
    Maniry, J.
    Reichert, T.
    Brenot-Rossi, I
    Niccoli, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 213 - 213
  • [22] Discordant Uptake Between Diagnostic 68Ga-HA-DOTATATE PET/CT and Posttherapy 177Lu-HA-DOTATATE SPECT/CT in Patients With Neuroendocrine Tumors
    Huizing, Daphne M. V.
    Aalbersberg, Else A.
    van der Hiel, Bernies
    Stokkel, Marcel P. M.
    Versleijen, Michelle W. J.
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E475 - E477
  • [23] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
    Kasi, Pashtoon Murtaza
    Maige, Catherine L.
    Shahjehan, Faisal
    Rodgers, Jessica M.
    Aloszka, Debora L.
    Ritter, Ashton
    Andrus, Margaret L.
    Mcmillan, Jessica M.
    Mody, Kabir
    Sharma, Akash
    Jain, Manoj K.
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [24] Early prediction of the efficacy of 177Lu-DOTATATE in patients with metastatic neuroendocrine tumors
    Bando-Delaunay, A.
    de Rycke, O.
    Hentic, O.
    Leclerc, P.
    Allouch, A.
    Cros, J.
    Rebours, V
    Ruszniewski, P.
    Lebtahi, R.
    de Mestier, L.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 176 - 176
  • [25] 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
    Poeppel, Thorsten D.
    Binse, Ina
    Petersenn, Stephan
    Lahner, Harald
    Schott, Matthias
    Antoch, Gerald
    Brandau, Wolfgang
    Bockisch, Andreas
    Boy, Christian
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (12) : 1864 - 1870
  • [26] Testicular Metastasis From Neuroendocrine Tumors: Imaging and Theranostics Through 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE-Based Peptide Receptor Radionuclide Therapy
    Parghane, Rahul V.
    Basu, Sandip
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (12) : 1051 - 1052
  • [27] Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors A Feasibility Study
    Thuillier, Philippe
    Maajem, Meriem
    Schick, Ulrike
    Blanc-Beguin, Frederique
    Hennebicq, Simon
    Metges, Jean-Philippe
    Salaun, Pierre-Yves
    Kerlan, Veronique
    Bourhis, David
    Abgral, Ronan
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (02) : 111 - 118
  • [28] Visual and whole-body quantitative analyses of 68 Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE
    Masatoshi Hotta
    Ida Sonni
    Pan Thin
    Kathleen Nguyen
    Linda Gardner
    Liliana Ciuca
    Artineh Hayrapetian
    Meredith Lewis
    David Lubin
    Martin Allen-Auerbach
    Annals of Nuclear Medicine, 2024, 38 : 296 - 304
  • [29] A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors
    Siebinga, H.
    de van der Veen, B. J.
    Beijnen, J. H.
    Stokkel, M. P. M.
    Dorlo, T. P. C.
    Huitema, A. D. R.
    Hendrikx, J. J. M. A.
    EJNMMI RESEARCH, 2021, 11 (01)
  • [30] Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Wild, Damian
    Bomanji, Jamshed B.
    Benkert, Pascal
    Maecke, Helmut
    Ell, Peter J.
    Reubi, Jean Claude
    Caplin, Martyn E.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (03) : 364 - 372